Document Detail


Long-term treatment of gastro-oesophageal reflux disease with omeprazole.
MedLine Citation:
PMID:  8047829     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reflux oesophagitis is a chronic disorder with frequent relapses on cessation of initial successful treatment. In patients with reflux oesophagitis, treatment with the acid pump inhibitor, omeprazole, has repeatedly been demonstrated to prevent the recurrence of symptoms and of erosive and/or ulcerative lesions in the oesophagus. Comparative trials have shown that an average of 82% of oesophagitis patients were maintained in endoscopic and symptomatic remission over a period of 12 months when treated with omeprazole, 20 mg once daily. This compares with only 36% of patients in remission when given 'full-dose' H2-receptor antagonist therapy (ranitidine, 300 mg daily). It is interesting to note that, in a recent trial, 62% of reflux oesophagitis patients were in remission after 12 months of treatment with omeprazole, 10 mg once daily, compared with the corresponding figure of 72% among those on 20 mg once daily. In patients poorly responsive to control of oesophagitis with H2-receptor antagonists, omeprazole at a dose of at least 20 mg daily is required to achieve symptom resolution and endoscopic healing--and remission can be maintained for years with continued omeprazole treatment. Omeprazole has been shown to have a good long-term safety profile, as evaluated in these trials.
Authors:
L Lundell
Related Documents :
3092659 - Comparison of enprostil and cimetidine in active duodenal ulcer disease. summary of poo...
6095659 - Results of the united states ranitidine maintenance trials.
3473639 - Treatment of xerostomia in patients with primary sjögren's syndrome with sulfarlem.
3440439 - Some adverse effects of disulfiram in the treatment of nickel-allergic patients.
22529599 - Pulmonary artery banding in the current era: is it still useful?
7827929 - Effect of ranitidine on soluble interleukin 2 receptors and cd8 molecules in surgical p...
24326659 - Superior masenteric vein thrombosis.
24378629 - A prospective randomized controlled study on the treatment outcome of spinecor brace ve...
23792029 - Patterns of hepatitis b surface antigen decline and hbv dna suppression in asian treatm...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Scandinavian journal of gastroenterology. Supplement     Volume:  201     ISSN:  0085-5928     ISO Abbreviation:  Scand. J. Gastroenterol. Suppl.     Publication Date:  1994  
Date Detail:
Created Date:  1994-09-01     Completed Date:  1994-09-01     Revised Date:  2008-02-13    
Medline Journal Info:
Nlm Unique ID:  0437034     Medline TA:  Scand J Gastroenterol Suppl     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  74-8     Citation Subset:  IM    
Affiliation:
Dept. of Surgery, Sahlgrenska Hospital, University of Gothenburg, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chronic Disease
Clinical Trials as Topic
Gastroesophageal Reflux / drug therapy*
Humans
Omeprazole / administration & dosage*
Chemical
Reg. No./Substance:
73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathophysiology of Helicobacter pylori infection.
Next Document:  Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux dis...